local_hospital

Riga East Clinical University Hospital

Address
Hipokrata iela 2, LV-1038 Riga, Latvia

Nervous System Diseases at Riga East Clinical University Hospital

Clinical research in this area focuses on acute ischemic stroke, a serious condition that can affect movement, speech, and long-term recovery. The trials are designed to assess whether new treatments can improve functional outcomes and support safer care after stroke.

  • Testing a new therapy to improve recovery after acute ischemic stroke
  • Evaluating treatment effectiveness for better neurological function
  • Monitoring safety concerns such as bleeding risk during stroke care

This work reflects an important effort to advance stroke treatment and improve outcomes for patients treated at the Riga East Clinical University Hospital.

Immune System Diseases

The site also studies immune system diseases, especially conditions linked to hypogammaglobulinemia and autoimmune or rheumatic conditions. These trials aim to help prevent serious infections in patients whose immune defenses are weakened by B-cell depletion therapy.

  • Preventing major infections in patients with weakened immune function
  • Supporting safer treatment for people with autoimmune and rheumatic conditions
  • Assessing whether immune-supportive therapy can reduce infection risk

By focusing on infection prevention, this research explores ways to protect vulnerable patients while they receive treatment for complex immune-related diseases.

Site Overview

assignment
2
connected trials
corporate_fare
2
sponsors
science
3
IMPs

Activity Indicator

Last 6 months

1
Trials started
New activity detected vs previous period.
0
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_upGrowing+100%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
2
Sponsors (total)
2
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 80 other sites in Latvia

description
Trial volume
2
Outperforms 34% of sites
public
Therapeutic diversity
2areas
Outperforms 55% of sites
groups
Sponsor diversity
2sponsors
Outperforms 40% of sites

Therapeutic Area Benchmark — Latvia

Select a therapeutic area to compare against other sites in Latvia.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Latvia

Market Share

Country: Latvia

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Riga East Clinical University Hospital

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Efficacy and Safety Evaluation of JX10 in Acute Ischemic Stroke Patients with Delayed Presentation: A Multicenter, Double-Blind, Placebo-Controlled, Randomized StudyCorxel Pharmaceuticals Co. Ltd.Phase IVRecruitingJul 2025

IMP list

lock Showing 1 of 3 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Human Normal Immunoglobulin1Unknown

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.